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Blood and marrow transplantation (BMT) is a standard curative therapy for patients with nonmalignant
genetic diseases. Myeloablative conditioning has been associated with signiﬁcant regimen-related toxicity
(RRT), whereas reduced-intensity conditioning regimens have been associated with graft failure. In this
prospective pilot trial conducted at 2 centers between 2006 and 2013, we report the outcome of 22 patients
with nonmalignant genetic diseases who were conditioned with a novel reduced-toxicity regimen: i.v.
busulfan (16 mg/kg), alemtuzumab (52 mg/m2), ﬂudarabine (140 mg/m2), and cyclophosphamide (105 mg/
kg). The median age of the study population was 3.5 years (range, 5 months to 26 years). No cases of sinu-
soidal obstruction syndrome, severe or chronic graft-versus-host disease (GVHD), or primary graft failure
were reported. Median time to neutrophil engraftment (>500 cells/mL) and platelet engraftment (>20K cells/
mL) were 19 (range, 12 to 50) and 23.5 (range, 14 to 134) days, respectively. The median length of follow-up
was 3 years (range, .2 to 6.3). The overall survival rates were 95% at 100 days (95% conﬁdence interval, .72 to
.99) and 90% at 6 years (95% conﬁdence interval, .68 to .98). RRT and chronic GVHD are signiﬁcant barriers to
BMT for patients with nonmalignant genetic diseases. This alemtuzumab-based reduced-toxicity regimen
appears to be promising with durable engraftment, effective cure of clinical disease, low rates of RRT, and no
observed chronic GVHD.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
For many patients with nonmalignant genetic diseases,
the decision burden regarding the immediate risks of blood
and marrow transplantation (BMT) versus continuation of
noncurative therapy often leads to delays in BMT. Unfortu-
nately, many of these patients present for BMT after they
have more advanced symptoms of their clinical disease, and
such delays may be associated with poorer outcomes [1].edgments on page 444.
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ty for Blood and Marrow Transplantation.BMT with a histocompatible-related donor after stan-
dard myeloablative conditioning (MAC) has been associated
with signiﬁcant regimen-related toxicity (RRT) [2-5]. The
nonmalignant genetic conditions represent a heteroge-
neous group of diseases with varying rates of RRT. These
toxicities include noninfectious pulmonary toxicity and
sinusoidal obstructive syndrome among patients with
hemophagocytic lymphohistiocytosis, a high rate of grade
II graft-versus-host disease (GVHD) among patients with
hemoglobinopathies, and a 9% graft failure rate among pa-
tients with thalassemia [6-8]. Interestingly, 30% of patients
who received matched sibling donor BMT for Hurler syn-
drome developed mixed chimerism, despite the use of MAC,
suggesting that sustained hematopoietic engraftment may
pose a challenge among some metabolic disorders [9]. An
Figure 1. Schematic diagram of the treatment regimen. The conditioning regimen consisted of i.v. ﬂudarabine (140 mg/m2), i.v. busulfan (16 mg/kg; with phar-
macokinetic dose adjustments to achieve overall target concentration steady state of 800 to 1000 ng/mL), alemtuzumab (52 mg/m2), and cyclophosphamide (105 mg/
kg). Either tacrolimus or cyclosporine was initiated on day 2 and continued for a minimum of 1 year post-transplant. Methylprednisolone (MPS) was tapered with a
goal of discontinuation by day þ35.
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BMT for nonmalignant genetic diseases must be associated
with low rates of RRT while remaining sufﬁciently immu-
noablative to allow for adequate levels of sustained donor
chimerism.
Although RRT associated with standard MAC regimens
(such as with busulfan, cyclophosphamide, and antithymo-
cyte globulin [ATG]) may be acceptable for patients with
leukemia whose disease may be immediately life threat-
ening, this is a major obstacle to the application of curative
BMT to nonmalignant genetic diseases. Reduction of the
cyclophosphamide dose may expose patients to an increased
risk of graft rejection, unless additional immunoablative
drugs are added to the regimen. In 2004, Sodeni et al. [10]
reported improved outcomes associated with dose reduc-
tion of cyclophosphamide and the addition of other agents to
achieve adequate immunosuppression. Bernaudin et al. [11]
showed that the addition of ATG to MAC regimens reduced
the rejection rate among hematopoietic stem cell trans-
plantation recipients with sickle cell disease from 22.6% to
3%. In the same year, we reported that the use of alemtuzu-
mab (a monoclonal antibody that binds to CD52 on mature
lymphocytes) was associated with reduced RRT, such as se-
vere GVHD [12]. We hypothesized that among patients with
nonmalignant genetic diseases receiving a matched related
donor BMT, the addition of alemtuzumab to a regimen of
busulfan, ﬂudarabine, and a reduced dose of cyclophospha-
mide would maintain adequate immune suppression, allow
acceptable rates of sustained donor engraftment, and allow
low rates of RRT and chronic GVHD.
METHODS
This prospective pilot study was approved by the institutional review
boards at Children’s Hospital Los Angeles and Stanford Lucile Packard
Children’s Hospital. Informed consent was obtained in accordance with the
Declaration of Helsinki.
Patients
Patients with nonmalignant genetic diseases who were candidates for
allogeneic transplantation at either institution between 2006 and 2013 and
had a 10/10 or 9/10 allele matched histocompatible sibling or related donor
were eligible for this study protocol. Subjects must have had adequate
physical and vital organ function, as measured by the following: (1) cardiac
shortening fraction >26% or left ventricular ejection fraction at rest >40%;
(2) bilirubin, alanine aminotransferase, and aspartate aminotransferase less
than 3 times the upper limit of normal (as per local laboratory) for age (with
the exception of isolated hyperbilirubinemia due to Gilbert syndrome); (3)
serum creatinine less than 2 times the upper limit of normal for age orcreatinine clearance or glomerular ﬁltration rate>50% lower limit of normal
for age; and (4) forced expiratory volume in 1 second, forced vital capacity,
and diffusing capacity of lung for carbon monoxide (corrected for hemo-
globin) >50% predicted or pulse oximetry oxygen saturation >92% on room
air. Patients with Karnofsky performance status <70% or Lansky <40%;
uncontrolled bacterial, viral, or fungal infections; seropositivity for HIV;
acute active hepatitis; diagnosis of end-organ dysfunction; or diagnosis of
severe combined immunodeﬁciency and Fanconi anemia were excluded.
Preparative Regimen
The conditioning regimen (Figure 1) consisted of i.v. ﬂudarabine at a
total dose of 140 mg/m2, i.v. busulfan at a total dose of 1 mg/kg/dose for 16
doses (with pharmacokinetic dose adjustments after dose 1 and then doses
5 and 7 if adjustments were made) to achieve an overall target concentra-
tion steady state of 800 to 1000 ng/mL, alemtuzumab (Campath 1H, Gen-
zyme Corporation, Cambridge, MA) at a total dose of 52 mg/m2, and
cyclophosphamide at a total dose of 105 mg/kg. Mesna was administered
per standard operating procedure at each institution.
GVHD Prophylaxis
GVHD prophylaxis (Figure 1) consisted of a calcineurin inhibitor and
methylprednisolone. Either tacrolimus or cyclosporine was initiated on
day 2 and titrated to maintain a serum trough level of approximately 7 to
10 ng/dL for tacrolimus or 200 to 300 ng/dL for cyclosporine. The drug was
continued for a minimum of 1 year post-transplant. Methylprednisolone
was administered at 2 mg/kg/day in divided doses at the start of the con-
ditioning regimen during the alemtuzumab infusion until day þ3. Subse-
quently, methylprednisolone was tapered with a goal of discontinuation by
day þ35.
Graft Source
Histocompatible bone marrow donors 10/10 or 9/10 allele-matched
were the main graft source on this protocol. One patient received a com-
bination of umbilical cord and marrow products from the same related
donor. The marrow was manipulated only for red blood cell or plasma
removal per standard institutional practice in event of an ABO-mismatch
between the donor and recipient.
Supportive Care
All patients remained hospitalized in protective isolation until therewas
evidence of engraftment of donor cells and sufﬁcient clinical recovery. Viral
prophylaxis consisted of i.v. acyclovir (1500 mg/m2/day) until day þ30 post-
BMT. If the donor or recipient were positive for cytomegalovirus (CMV)
serology, CMV PCR assays were sent at a minimum of weekly until dayþ100
post-BMT. If patients developed CMV viremia, ganciclovir (5 mg/kg) was
administered intravenously twice daily. Pneumocystis carinii pneumonia
prophylaxis consisted of oral trimethoprim-sulfamethoxazole 75 mg/m2 or
2.5 mg/kg trimethoprim twice daily from admission until day 2 post-BMT.
Pneumocystis carinii pneumonia prophylaxis was resumed after count re-
covery, per institutional practice. Standard antifungal prophylaxis consisted
of ﬂuconazole orally or intravenously 5 mg/kg until at least day þ100 post-
BMT. Standard antiseizure prophylaxis was administered. Patients with
sickle cell disease continued antiseizure prophylaxis until discontinuation of
calcineurin inhibitors.
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This was a prospective pilot study to evaluate the safety and efﬁcacy of
the proposed regimen among this patient population. A minimum of 20
patients were targeted for enrollment between 2006 and 2013. Stop criteria
was established at a graft failure rate of more than 10% and/or an unexpected
toxicity rate of more than 30%.
Neutrophil engraftment was deﬁned as the ﬁrst day of 3 consecutive
days when the absolute neutrophil count exceeded 500/mm3. Hematolog-
ical recovery of donor origin was conﬁrmed by short tandem repeat or
ﬂuorescent in situ hybridization. This analysis was repeated at 1 year post-
BMT and if there was a concern regarding graft stability. Disease-speciﬁc
observations such as enzymes levels or hemoglobin electrophoresis were
routinely performed on days 100, 180, 270, and 360 after BMT. Platelet
engraftment was deﬁned as the ﬁrst day of a minimum of 3 consecutive
measurements on different days when the platelet count exceeded 20,000/
mm3 and the patient was platelet transfusion-independent for a minimum
of 7 days. Time to T lymphocyte recovery was deﬁned by the absolute
number of donor-derived CD3þ T lymphocytes >500/mm3 and phytohe-
magglutinin response >25,000 CPM of tritiated thymidine incorporation.
Time to antigen-speciﬁc T lymphocyte function was deﬁned as a proliferate
response to tetanus toxoid of greater than 3 times the background prolif-
eration (stimulation index ¼ 3).
To study pharmacokinetic clearance of alemtuzumab, levels were drawn
on days 7, 14, 21, and 28 after BMT. Assays were performed as previously
described [12]. No dose adjustments were made. Acute GVHD was assessed
by the Glucksberg staging criteria [13]. Chronic GVHD was assessed by
criteria of the National Institutes of Health Consensus Development Project
on criteria for clinical trials in chronic GVHD [14]. Overall survival of subjects
was estimated using Kaplan-Meier analysis.RESULTS
Patient Characteristics
As shown in Table 1, the study populationwas 68% female
(n ¼ 15), 41% Hispanic (n ¼ 9), 23% black (n ¼ 5), 23% white
(n ¼ 5), and 14% Asian (n ¼ 3). The median age was 3.5 years
(range, 5 months to 26 years). Pre-transplant diagnoses
included sickle cell disease (n¼ 7), thalassemia (class I: n¼ 1;
class II: n ¼ 3), Hurler syndrome (n ¼ 2), diamond blackfan
anemia (n ¼ 2), Kostmann syndrome (n ¼ 2), Griscelli syn-
drome (n ¼ 2), chronic granulomatous disease (n ¼ 1),Table 1
Patient and Graft Characteristics and Outcomes
UPN Diagnosis Ethnicity Age at
BMT
(yr)
CMV
Status
R/D
Sex
Matc
R/D
3715 Hurler syndrome Hispanic 1.8 / F/F
3757 Hurler syndrome White 1.2 / F/M
3825 Diamond-blackfan anemia Unspeciﬁed 26 / F/F
997 Sickle cell disease Hispanic 2.9 þ/þ M/M
1002 Sickle cell disease Black 14.2 /þ M/F
1008 Kostmann syndrome White .6 /þ M/F
4096 Diamond-blackfan anemia Hispanic 3.4 þ/þ F/F
1033 Kostmann syndrome Hispanic 6.4 þ/þ F/M
1043 Chronic granulomatous disorder Hispanic 9.3 / M/F
1108 Sickle cell disease Black 9.5 / M/M
1113 Hemoglobin H thalassemia Asian 7.8 þ/þ F/F
4631 Cartilage hair hypoplasia White 2.3 þ/ F/M
1127 Chediak-Higashi syndrome White/Hispanic 1.6 /þ F/M
1151 Sickle cell disease Hispanic 11.8 /þ F/M
4817 Thalassemia Middle Eastern 6.0 þ/þ F/F
4970 Thalassemia Asian 7.0 / M/M
1184 Sickle cell Anemia Black 7.6 / F/F
5034 Griscelli syndrome Hispanic .8 /þ M/F
1200 Griscelli Syndrome/
hemophagocytic
lymphohistiocytosis
Hispanic .4 / F/M
5433 Sickle cell disease Black 8.0 / F/M
5519 Thalassemia Asian 2.0 /þ F/M
1299 Sickle cell anemia Black 4.5 / F/M
R/D indicates recipient/donor; ANC, absolute neutrophil count.cartilage hair hypoplasia (n ¼ 1), and Chediak-Higashi
syndrome (n ¼ 1).
Transplant Characteristics
The mean busulfan concentration steady state and area
under the curve were 890 (211) mg/L and 1285 (387)
mmol/L-min. Alemtuzumab levels were available for 11 pa-
tients at Children’s Hospital Los Angeles. The median time to
clearance of alemtuzumab was 14 days (range, 3 to 21 days).
All patients received 10/10 related donor transplant. Two
patients received 10/10 marrow donor transplants from a
parent, and 1 patient received a combination of marrow and
cord from a related sibling. The median total nucleated cell
(TNC) count and CD34 dose was 4.6  108 cells/kg (range, 1.6
to 9.2  108) and 7.6  106 cells/kg (range, 2.4 to 23.3  106),
respectively.
Engraftment/Immune Reconstitution
The median times to neutrophil engraftment (>500 cells/
mL) and platelet engraftment (>20K cells/mL) were 19 (range,
12 to 50) and 23.5 (range, 14 to 134) days, respectively. All 22
patients achieved initial donor hematopoietic stem cell
engraftment. Two patients required additional treatment
post-BMT. One patient with thalassemia (UPN 4817) required
a stem cell boost on day þ83. Her mean busulfan level was
785 mg/L. Alemtuzumab levels were not performed for this
patient. She received a TNC count and CD34 dose of 2.0 108
cells/kg and 2.8  106 cells/kg, respectively. She experienced
poor count recovery associated with CMV viremia. Her initial
chimerism on day 50was 63% donor. However, after the stem
cell boost she has remained 90% donor.
One patient with Hurler syndrome (UPN 3757) required 6
courses of donor lymphocyte infusions (DLIs). Her mean
busulfan level was 920 mg/L. Alemtuzumab levels were not
done for this patient. She received a TNC count and CD34
dose of 5.4  108 cells/kg and 7.2  106 cells/kg, respectively.h
ABO
R/D
TNC
(108/kg)
CD34
(106/kg)
ANC
Engraftment
Day
Post-BMT
Platelet
Engraftment
Day
Post-BMT
Last
Follow-
Up (yr)
Oþ/Oþ 4.3 7.7 19 22 4.5
Aþ/Aþ 5.4 7.2 31 54 6
Aþ/Bþ 4.7 4 13 22 4.1
Oþ/Oþ 6.8 8.5 34 50 6
Aþ/Aþ 3.7 2.4 18 80 1.8
A-Bþ 5.6 14.0 28 31 5.5
O/Oþ 4.6 7.5 38 84 6.3
Bþ/Bþ 3.5 6.3 16 23 5.1
Aþ/Oþ 6.4 6.6 15 94 4.9
Bþ/Oþ 5.9 5.8 19 20 .8
Oþ/Bþ 4.9 14.4 14 18 3.5
Oþ/Oþ 1.1 .2 19 30 3.0
ABþ/Aþ 5.6 15.2 19 14 3.1
Oþ/Oþ 4.6 4.2 13 18 2.8
O/Aþ 2.0 2.8 50 134 2.6
Aþ/Aþ 1.6 10.3 24 24 .5
Bþ/Aþ 2.0 6.8 16 15 2.1
Aþ/Aþ 7.9 10.6 12 17 .2
Oþ/Aþ 9.2 13.4 19 25 2
Bþ/Bþ 2.6 10.6 21 75 .8
Bþ/Oþ 6.4 23.3 14 19 .7
Aþ/Aþ 4.3 5.3 18 74 .7
Table 2
Hematopoietic Reconstitution
Hematopoietic Reconstitution Median Time (days)
ANC engraftment (>500 cells/mL) 19 (range, 12-50)
Platelet engraftment (>20K cells/mL) 23.5 (range, 14-94)
Donor-derived CD3þ T lymphocytes >500/mm3 174 (range, 99-374)
Phytohemagglutinin response >25,000 CPM 169 (range, 97-316)
Antigen-speciﬁc T lymphocyte function 181 (range, 97-218)
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donor percent ranged from 18% to 43% during her courses of
DLI. At 6 years post-BMT she has stable donor engraftment
with 58% CD3 and 66% whole blood donor chimerism.
Table 2 summarizes immune reconstitution data available
for 11 patients at Children’s Hospital Los Angeles.Median time
to T lymphocyte recovery and phytohemagglutinin response
>25,000 CPMwas 174 (range, 99 to 374) and 169 (range, 97 to
316) days, respectively. Median time to antigen-speciﬁc T
lymphocyte function was 181 days (range, 97 to 218).
RRT/Late Effects
There were no cases of grades III to IV acute or chronic
GVHD. Ten patients developed grades I to II skin late-onset
acute GVHD, and 1 patient developed grade II acute GVHD
of the gut; the median time to onset of GVHD was 204 days.
Sixteen patients have been followed in excess of 1 year and
none has chronic GVHD.
There were no reported cases of sinusoidal obstructive
syndrome. Median time to onset of infectious complications
was 27 days (range, 6 to 282). Infectious complications
included CMV viremia (n ¼ 5), Epstein-Barr viremia (n ¼ 1),
mucormycosis (n ¼ 1), and adenoviremia (n ¼ 1). Two pa-
tients died: 1 patient with thalassemia died from interstitial
pneumonitis on dayþ187 post-BMT (UPN4970) and the other
patient with Griscelli syndrome died from mucormycosis on
day þ67 post-BMT (UPN 5034). She had been maintained on
standard prophylaxis when she was diagnosed. No late effects
of BMT such as secondary malignancy, endocrine failures, and
end-organ toxicities have been reported.
Overall and Disease-Free Survival
The median length of follow-up was 3 years (range, .2 to
6.3). Rates of overall survival were 95% at 100 days (95%
conﬁdence interval, .72 to .99) and 90% (95% conﬁdence in-
terval, .68 to .98) at 6 years. All patients (100%) have sus-
tained predominant donor chimerism, with effective cure of
their clinical disease and a Lansky/Karnofsky performance
score of 100.
DISCUSSION
Nonablative regimens based on low-dose radiation (200
to 400 cGy) and ﬂudarabine used to reduce RRT have been
associated with poor rates of engraftment, especially among
patients with hemoglobinopathies [15,16]. Lucarelli and
Gaziev [17] reviewed the international experience in thal-
assemia and sickle cell disease and showed overall poor re-
sults and a reduced rate of sustained engraftment (only 1 in
11 transplants) with nonmyeloablative approaches [17]. A
small cohort of adult patients with sickle cell disease (n¼ 11)
conditioned with 300 cGy of total body irradiation and
alemtuzumab showed promising results. Whether this
regimen will have similar results among thalassemia pa-
tients remains to be seen [18]. With our current regimen, all
patients with sickle cell disease (n ¼ 7) achieved and sus-
tained high-level donor chimerism (>99% donor). During thepreparation of this article, Bhatia et al. [19] reported suc-
cessful engraftment in a cohort of patients with sickle cell
disease who received myeloablative busulfan and ﬂudar-
abine and alemtuzumab but without cyclophosphamide
before matched sibling donor transplant. Because patients
with thalassemia and Hurler syndrome have historically
been affected by higher rates of graft failure, we chose to
judiciously de-escalate cyclophosphamide. The promising
rates of engraftment associated with this regimen now raises
the question as to whether further reductions in cyclophos-
phamide are possible and whether the current regimen can
be successfully used in the unrelated donor setting.
Although the combination of myeloablative doses of
busulfan and high doses of cyclophosphamide have been
extensively used for immunocompetent patients with
nonmalignant diseases, several studies have also shown the
importance of some form of antibody-based lymphotoxic
therapy (ATG, alemtuzumab) in the conditioning regimen.
Bernaudin et al. [11] observed nonengraftment rates of 22.6%
in patients with sickle cell diseasewho received busulfan and
cyclophosphamide alone versus 2.9% in those who received
busulfan, cyclophosphamide, and ATG as conditioning.
Because lymphotoxic antibodies persist after stem cell infu-
sion, they may both decrease the risk of GVHD but delay
immune reconstitution. Either ATG or alemtuzumab has
been shown to lower GVHD rates in a variety of transplant
settings, including unrelated, mismatched, and non-
myeloablative transplants.
RRT is believed to be a major contributing factor to GVHD
[19]. Therefore, conditioning regimens that cause less tissue
injury may be associated with reduced rates of GVHD.
Additionally, T cell depletion, such as occurs with the use of
alemtuzumab, may be associated with reduced rates of
GVHD [12,20-21]. Among patients with sickle cell disease
undergoing sibling donor BMT with MAC, GVHD remains a
signiﬁcant complication [5,22].
In this current study, using an alemtuzumab-containing
regimen, there were no cases of severe acute or extensive
chronic GVHD. This is noteworthy, because there is no sur-
vival advantage to development of GVHD for patients with
sublethal genetic diseases. It is interesting to note that the
median time to onset of mild GVHD in this group was 204
days, with 8 patients experiencing mild late-onset acute
GVHD. Such low rates of acute GVHD and no chronic GVHD
offer promise for this regimen in the unrelated donor setting,
which we are currently studying.
We previously reported that use of alemtuzumab as part
of conditioning may be associated with a higher rate of viral
infections without an increased rate of infectious-related
mortality [12]. Indeed, although 20% of our patients did
experience infectious morbidity, data available on the subset
of patients who underwent BMT at Children’s Hospital Los
Angeles suggest this regimen is associated with prompt
immune reconstitution. Among all patients, onset of infec-
tious complications was primarily restricted to the ﬁrst 30
days. Hence, appropriate measures to reduce infectious
morbidity and mortality may be important in the early
period after BMT for patients treated with this regimen.
Although the decrease in the dose of cyclophosphamide in
this regimen was aimed primarily at reducing the early
complications associated with MAC, it is possible the poten-
tially dose-dependent late effects associated with cyclophos-
phamide, such as gonadal failure and secondarymalignancies,
may also be minimized with this regimen [23-25]. At a me-
dian of 3 years of follow-up, no late effects of BMT, such as
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toxicities, have been observed. Further reduction or removal
of cyclophosphamide from this regimen could be associated
with improved outcomes by decreasing acute toxicity further.
However, the risks of nonengraftment and/or need for DLI,
especially among patients with hemoglobinopathies and/or
Hurler syndrome, must be considered.
For patients with nonmalignant genetic diseases, early
RRT, nonengraftment, and chronic GVHD may serve as po-
tential barriers to successful BMT. This novel preparative
regimen is promising, because it is associated with durable
donor engraftment, 90% overall survival rate, low rates of
early regimen-related complications (such as sinusoidal
obstructive syndrome and acute GVHD), and no chronic
GVHD. Longer follow-up is required to assess for a potential
reduction in late effects associated with this regimen, such as
gonadal failure and secondary malignancies.
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